Last reviewed · How we verify

Associazione Volontari Pazienti Oncologici — Portfolio Competitive Intelligence Brief

Associazione Volontari Pazienti Oncologici pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
RT+CDDP/5-FU RT+CDDP/5-FU phase 3 Platinum-based chemotherapy Oncology
RT+CETUXIMAB RT+CETUXIMAB phase 3 EGFR inhibitor (monoclonal antibody) + radiation therapy combination EGFR (epidermal growth factor receptor) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. Barts & The London NHS Trust · 1 shared drug class
  3. CatalYm GmbH · 1 shared drug class
  4. Centre Leon Berard · 1 shared drug class
  5. Centre Oscar Lambret · 1 shared drug class
  6. Chinese Academy of Medical Sciences · 1 shared drug class
  7. Chinese Anti-Cancer Association · 1 shared drug class
  8. Air Force Military Medical University, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Associazione Volontari Pazienti Oncologici:

Cite this brief

Drug Landscape (2026). Associazione Volontari Pazienti Oncologici — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/associazione-volontari-pazienti-oncologici. Accessed 2026-05-17.

Related